MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtemb.2025.127778

Медицинская библиотека · Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2025

Zinc adjuvant treatment in SARS-CoV-2: A randomized clinical trial.

Gómez-Zorrilla Silvia, Sendra Elena, Du Juan, Espona Mercé, Fierro-Villegas Alejandro, Siverio Ana, Rodriguez-Alarcón Alicia, Castañeda Silvia, López Montesinos Inmaculada, Plata Cristina, Arrieta-Aldea Itziar, Soldado-Folgado Jade, García-Giralt Natalia, Vicente Rubén, Güerri-Fernández Robert

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Zinc is a trace element with a key role in immune function and has demonstrated antiviral and anti-inflammatory properties. Low plasma zinc levels have been associated with poor outcomes in COVID-19. This study aims to evaluate the efficacy and safety of zinc supplementation as an adjuvant therapy in hospitalized patients with COVID-19.

METHODS

A single-center, randomized, open-label clinical trial between May and December 2021. Adults hospitalized with confirmed COVID-19 requiring hospitalization were randomized 1:1 to receive standard of care (SoC) with or without oral zinc acetate (90 mg/day) for 14 days. The primary endpoint was disease progression, defined as critical care requirement (ICU admission) or death. Secondary outcomes included time to clinical recovery, hospital length of stay, WHO clinical scale improvement, inflammatory markers, antibody response, and safety.

RESULTS

Seventy-one patients were randomized (35 zinc versus 34 SoC). Disease progression occurred in 5.7 % of the zinc group versus 23.5 % in the SoC group (OR 0.21, 95 %CI = 0.03-0.96,). Mean recovery time was significantly shorter in the zinc group (7.4 ± 6.1 versus 13.1 ± 9.7 days, p = 0.006) and a trend to a faster recovery was observed in the Cox proportional hazards model in the intervention group HR of 1.670 (95 % CI: 0.948-2.942), p = 0.076. WHO scale improvement attaining a < 1 points at day 14 was greater in the zinc group (74.3 % versus 42.4 %, p = 0.009). Antibody levels were higher in the SoC group at days 14 and 28. No adverse events were attributed to zinc.

CONCLUSIONS

Adjunctive zinc supplementation to standard of care reduced disease progression and showed a trend to accelerated clinical recovery in hospitalized COVID-19 patients, supporting the potential role of zinc in managing viral respiratory infections.

TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT05778383.

Для цитирования: Gómez-Zorrilla Silvia, Sendra Elena, Du Juan, Espona Mercé, Fierro-Villegas Alejandro, Siverio Ana, Rodriguez-Alarcón Alicia, Castañeda Silvia, López Montesinos Inmaculada, Plata Cristina, Arrieta-Aldea Itziar, Soldado-Folgado Jade, García-Giralt Natalia, Vicente Rubén, Güerri-Fernández Robert. Zinc adjuvant treatment in SARS-CoV-2: A randomized clinical trial.. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS). 2025. DOI: 10.1016/j.jtemb.2025.127778.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.